Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancer

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Kim, Ryung S ^a   Avivar Valderas, Alvaro ^b   Estrada, Yeriel ^b   Bragado, Paloma ^b   Sosa, Maria Soledad ^b   Aguirre Ghiso, Julio A ^b   Segall, Jeffrey E ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; SMALL INTERFERING RNA;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER RECURRENCE; CANCER RISK; CLINICAL STUDY; CONTROLLED STUDY; GENE REPRESSION; GENETIC IDENTIFICATION; HIGH DORMANCY SCORE; HUMAN; HUMAN CELL; IN VIVO STUDY; LOW DORMANCY SCORE; METASTASIS; METASTASIS POTENTIAL; ONCOGENE; ONCOGENE BHLHE41; ONCOGENE NR2F1; SCORING SYSTEM; TREND STUDY;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, SCID; NEOPLASM METASTASIS; RECEPTORS, ESTROGEN; RNA INTERFERENCE; SURVIVAL ANALYSIS;

EID: 84859994398     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035569     Document Type: Article

References (23)

1. Naumov GN, Townson JL, MacDonald IC, Wilson SM, Bramwell VH, et al. (2003) Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat 82: 199-206.
2. Muller V, Stahmann N, Riethdorf S, Rau T, Zabel T, et al. (2005) Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 11: 3678-3685.
3. Pantel K, Brakenhoff RH, (2004) Dissecting the metastatic cascade. Nat Rev Cancer 4: 448-456.
4. Aguirre-Ghiso JA, (2007) Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7: 834-846.
5. Vessella RL, Pantel K, Mohla S, (2007) Tumor Cell Dormancy: An NCI Workshop Report. Cancer Biol Ther 6.
6. Adam AP, George A, Schewe D, Bragado P, Iglesias BV, et al. (2009) Computational identification of a p38SAPK-regulated transcription factor network required for tumor cell quiescence. Cancer Res 69: 5664-5672.
7. Almog N, Ma L, Raychowdhury R, Schwager C, Erber R, et al. (2009) Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res 69: 836-844.
8. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, et al. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515-527.
9. Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, et al. (2007) The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 1: 84-96.
10. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, et al. (2007) Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25: 1239-1246.
11. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, et al. (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671-679.
12. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, et al. (2005) Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7: R953-964.
13. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009.
14. Klopp AH, Lacerda L, Gupta A, Debeb BG, Solley T, et al. (2010) Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells. PLoS One 5: e12180.
15. Early Breast Cancer Trialists' Collaborative Group E (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717.
16. Tran B, Bedard PL, (2011) Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res 13: 221.
17. Takekawa M, Tatebayashi K, Itoh F, Adachi M, Imai K, et al. (2002) Smad-dependent GADD45beta expression mediates delayed activation of p38 MAP kinase by TGF-beta. Embo J 21: 6473-6482.
18. McGillicuddy FC, O'Toole D, Hickey JA, Gallagher WM, Dawson KA, et al. (2006) TGF-beta1-induced thrombospondin-1 expression through the p38 MAPK pathway is abolished by fluvastatin in human coronary artery smooth muscle cells. Vascul Pharmacol 44: 469-475.
19. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, et al. (2009) A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 137: 87-98.
20. Li C, Wong WH, (2003) DNA-Chip Analyzer (dChip). In: Parmigiani G, Garrett ES, Irizarry R, Zeger SL, editors. The analysis of gene expression data: methods and software New York Springer pp. 120-141.
21. Hollander MW, Douglas A, (1973) Nonparametric Statistical Methods New York John Wiley & Sons.
22. Andersen PG, Gill RD, (1982) Cox's regression model for counting processes, a large sample study. Annals of Statistics 10: 1100-1120.
23. Team RDC (2009) R: A language and environment for statistical computing Vienna, Austria R Foundation for Statistical Computing.